Tag

geriatric assessment Archives | Carevive - cancer care management & patient engagement tools

Events

Carevive to Present Two Posters at the 2019 MASCC/ISOO Annual Meeting

Carevive's Director of Research, Debra Wujcik, PhD, RN, FAAN, will be presenting two posters at the 2019 MASCC/ISOO Annual Meeting in San Francisco on June 21-23.  The posters explore the usage of Carevie's patient-reported outcomes (PROs) tools to assess cancer pain associated with severe flares and end-of-dose failure and how chronic lymphocytic leukemia (CLL) patients can benefit from the collection…
Carevive
June 20, 2019
CME

Multiple Myeloma in 2019: Maintenance Therapy & Treatment Side Effect Management

Release Date: 6/7/2019 Expiration Date: 6/6/2020 Physicians – Maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses – 0.6 contact hours (0.3 pharmacotherapy) Target Audience The target audience for this activity is U.S.-based hematologists/oncologists, hematology/oncology NPs/PAs, and registered nurses. Faculty Rafael Fonseca, MD, FACP Mayo Clinic – Arizona Beth Faiman, PhD, APRN-BC, AOCN Cleveland Clinic Educational Objectives After completing this activity, the participant should be…
Carevive
June 18, 2019
CME

Multiple Myeloma in 2019: Updates and Clinical Trial Data

Release Date: 6/7/2019 Expiration Date: 6/6/2020 Physicians – Maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses – 0.6 contact hours (0.3 pharmacotherapy) Target Audience The target audience for this activity is U.S.-based hematologists/oncologists, hematology/oncology NPs/PAs, and registered nurses. Faculty Rafael Fonseca, MD, FACP Mayo Clinic – Arizona Educational Objectives After completing this activity, the participant should be better able to: Consider clinical trial data…
Carevive
June 18, 2019
CME

Multiple Myeloma in 2019: The Geriatric Assessment Tool and Clinical Evidence

Release Date: 6/7/2019 Expiration Date: 6/6/2020 Physicians – Maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses – 0.5 contact hours Target Audience The target audience for this activity is U.S.-based hematologists/oncologists, hematology/oncology NPs/PAs, and registered nurses. Faculty Tanya Wildes, MD, MSCI Washington University School of Medicine Educational Objectives After completing this activity, the participant should be better able to: Consider real-world evidence when managing…
Carevive
June 7, 2019
CME

What’s New in Acute Myelogenous Leukemia?

Release date: October 17, 2018 
Expiration date: October 16, 2019 Estimated time to complete activity: 0.75 hours Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit…
Carevive
October 17, 2018
CME

Geriatric Assessment in Older Patients with AML: Treatment Updates and Implications

Release date: October 17, 2018 
Expiration date: October 16, 2019 Estimated time to complete activity: 0.5 hours Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit…
Carevive
October 17, 2018
PostersResources

Impact of a Brief Touchscreen Based, Modified Geriatric Assessment (mGA) on the Care of Older Adults with Multiple Myeloma

The Carevive team along with investigators from City of Hope, Rochester University, University of Arizona, and Mt Sinai are presenting a poster at the 59th ASH annual meeting, "Impact of a Brief Touchscreen Based, Modified Geriatric Assessment (mGA) on the Care of Older Adults with Multiple Myeloma". The purpose of the study was to test the feasibility of conducting a…
Carevive
November 27, 2017